ClinicalTrials.gg
RecruitingNCT06843928Updated Feb 25, 2025

The Adjunctive Effect of a Titanium Brush in the Non-Surgical Treatment of Peri-Implantitis

An interventional study of Submucosal debridement and Submucosal debridement + titanium brushes in Peri-implantitis, Titanium Brush and Non-surgical Submucosal Debridement, sponsored by Universitat Internacional de Catalunya. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Universitat Internacional de Catalunya · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Jun 2024, registered Dec 2024).
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya — 6 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Universitat Internacional de Catalunya.

Started
2024
with 1 other
No phase
7 of 15
4 open now
Registered
14th of 15
by date

Among the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, this one is one of 2 that started in 2024, is one of 7 with no phase, and was the 14th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

6 of the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, or all of them as a file.
02

Study summary

Peri-implantitis is a plaque-associated condition occurring around dental implants, characterized by inflammation in the peri-implant mucosa and loss of supporting bone. To stop this progression, mechanical debridement of biofilm and calculus is commonly used to treat peri-implant lesions as well as the use of adjunctive measures such as titanium brushes. As observed, they improved plaque removal when compared with steel curettes alone. Therefore, it is of interest to evaluate the impact of this procedure in terms of clinical, radiographic and microbiological outcomes to assess their efficacy.

03

Conditions studied

  • Peri-implantitis
  • Titanium Brush
  • Non-surgical Submucosal Debridement

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with ≥18 years of age.
  • Ability to understand all the study procedures and to comply with them along the entire study period. Ability and willingness to give written .
  • An adequate level of oral hygiene (plaque index ≤ 25%) (O'Leary et al., 1972).
  • Treated periodontal disease.
  • Presence of at least one titanium implant with peri-implantitis [i.e., presence of bleeding and/or suppuration on gentle probing with probing depth of ≥6 mm, and progressive bone loss. In the absence of initial radiographs, a bone level ≥2 mm apical to the most coronal part of the intrabony portion of the implant will be used as threshold of disease (Romandini et al., 2021)].
  • Horizontal and vertical peri-implant bone defects.
  • Implant function time ≥ 1 year.
  • Presence of ≥2mm of keratinized peri-implant mucosa.
  • Screw-retained single and multiple restorations.

Exclusion criteria

Exclusion Criteria:

  • Untreated periodontitis.
  • Smokers > 10 cigarettes per day.
  • Local or systemic diseases that would interfere with routine periodontal therapy (i.e., uncontrolled diabetes mellitus, cancer, , chronic high-dose therapy, metabolic bone disease, radiation, disease, hepatic dysfunction, immunosuppressive disease, disease).
  • Pregnant or lactating women.
  • Previous surgical and non-surgical treatment of affected implants at least 12 months prior to the beginning of the study.
  • Radiographic peri-implant bone loss > two-thirds.
  • Mobility of the implant.
  • Known allergy or intolerance to macrolides.
  • Use of systemic antibiotics during the last 3 months.
  • Need of endocarditis prophylaxis.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Participants will receive submucosal debridement alone

    Device: Submucosal debridement · Device: Submucosal debridement + titanium brushes

  • Experimental
    Test Group

    Participants will receive submucosal debridement and titanium brushes

    Device: Submucosal debridement · Device: Submucosal debridement + titanium brushes

Interventions

  • DeviceSubmucosal debridement

    Participants will undergo non-surgical submucosal debridement alone (SD)

  • DeviceSubmucosal debridement + titanium brushes

    Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)

06

What researchers measure

Primary outcomes

  1. Pocket depth changes

    The primary outcome variable will be pocket depth changes at 1 year of follow-up.

    Time frame: 12 Months

Secondary outcomes

  1. Full mouth plaque index (FMPI)

    Assessed dichotomously as presence or absence of plaque will be scored if present along the gingival margin and if it can be removed with the side of the probe. The percentage of surfaces with plaque out of the total number of examined tooth surfaces will be calculated.

    Time frame: 12 Months

  2. Full mouth bleeding index (FMBI)

    Assessed dichotomously as presence or absence of bleeding after 30 seconds of gently probing. The proportion of bleeding surfaces out of the total number of examined surfaces will be calculated.

    Time frame: 12 Months

  3. Modified plaque index (mPI)

    * Score 0: no detection of plaque. * Score 1: plaque only recognized by running a probe across the smooth marginal surface of the implant. * Score 2: plaque can be seen by the naked eye. * Score 3: abundance of soft matter.

    Time frame: 12 Months

  4. Modified bleeding index (mBI)

    * Score 0: no bleeding. * Score 1: isolated bleeding spots visible. * Score 2: blood forms a confluent red line on margin. * Score 3: heavy or profuse bleeding.

    Time frame: 12 Months

  5. Suppuration on probing (SoP)

    Presence or absence of suppuration after gentle probing.

    Time frame: 12 Months

  6. Mucosal recession (MR)

    Distance (mm) from the mucosal margin and the interface between implant and abutment.

    Time frame: 12 Months

  7. Keratinized mucosa (KM)

    Distance (mm) from the mucosal margin to the mucogingival junction at the midbuccal aspect of the implant.

    Time frame: 12 Months

  8. Radiographic parameters

    Marginal bone level (MBL): distance (mm) between the implant shoulder and the base of the defect at the mesial and distal aspect.

    Time frame: 12 Months

  9. Radiographic parameters

    Intra-bony defect (ID): distance (mm) between the bottom of the defect and the line connecting the distal and mesial inter-proximal bone crest.

    Time frame: 12 Months

  10. Radiographic parameters

    Intra-bony defect width (WD): distance (mm) between the distal and mesial inter- proximal bone crest and the implant surface.

    Time frame: 12 Months

  11. Radiographic parameters

    Angulation of the intra-bony defect (AD): angle resulted from a vertical line along the outer implant surface and a line extending along the peri-implant bone defect.

    Time frame: 12 Months

  12. Microbiological analysis

    Total bacterial load (CFU/ml) Microbiome alpha-diversity

    Time frame: 12 Months

  13. Microbiological analysis

    Total bacterial load (CFU/ml) Microbiome beta-diversity

    Time frame: 12 Months

  14. Microbiological analysis

    Total bacterial load (CFU/ml) Relative and differential bacterial genera abundance at different timepoints

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jul 2025, 13 months after the start.

Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 13 months is below that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Feb 25, 2025
StartActual
Jun 12, 2024
Primary completionEst.
Jul 17, 2025
CompletionEst.
Jul 16, 2026
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06843928
Responsible party
Javi Vilarrasa (Clinical Professor, Universitat Internacional de Catalunya) — Principal investigator
First posted
Feb 25, 2025
Start date
Jun 12, 2024
Primary completion
Jul 17, 2025 (estimated)
Completion
Jul 16, 2026 (estimated)
Last update
Feb 25, 2025

Study contacts

Javi Vilarrasa
Contact
jvilarrasa@uic.es
+34 628553000
Fares Al Hajeb
Contact
faresalhajeb@uic.es
+34 696062892

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion